STAAR Surgical FY 2025 earnings snapshot

STAAR Surgical (STAA) has wrapped up FY 2025 with Q4 revenue of US$57.8 million and a basic EPS loss of US$0.37, keeping the focus firmly on the path back to profitability. The company has seen quarterly revenue range from US$42.6 million to US$94.7 million since the start of 2024, while basic EPS has swung between a loss of US$1.10 and a profit of US$0.20. This sets up a mixed picture on margins that investors may view as an ongoing turnaround story rather than a completed one.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the widely followed narratives around growth, profitability and the timing of any margin recovery.

Losses still heavy at US$80.4 million over the year

• On a trailing 12 month basis to Q4 2025, STAAR Surgical reported total revenue of US$239.4 million and a net loss of US$80.4 million, with basic EPS at a loss of US$1.62.
• Bears highlight that losses have been expanding over the past five years, and the latest trailing figures still show negative earnings. They argue this keeps execution risk front and center even as quarterly revenue has ranged between US$42.6 million and US$94.7 million.
  • Critics point to the 57.6% annual loss growth rate over five years and the FY 2025 net loss of US$80.4 million as evidence that profitability has not yet taken hold, challenging any idea that the turnaround is already reflected in the financials.
  • They also note that basic EPS flipped between profits in Q3 2025 and Q3 2024 and losses in the surrounding quarters. To them, this suggests that earnings are still volatile around a loss making base rather than steadily moving higher.

If you are trying to decide whether that kind of loss profile justifies the current risk, it can help to read how skeptics frame the downside case in detail. 🐻 STAAR Surgical Bear Case

12.1% revenue growth vs market supports the bull case

• Over the last 12 months, revenue growth of 12.1% per year has outpaced the 10.2% per year benchmark for the US market, even though the company remained loss making on a trailing basis.
• Bulls argue that this above market top line growth, combined with forecasts that earnings could grow 91.38% per year and reach profitability within three years, heavily supports a turnaround thesis even while trailing 12 month basic EPS is a loss of US$1.62.
  • Supporters point out that quarterly revenue reached US$94.7 million in Q3 2025 versus US$42.6 million at the low end in FY 2025. They see that range as evidence that the product set can support higher volumes when conditions are favorable.
  • They also anchor on the forecasted move from an LTM net loss of US$80.4 million to positive earnings, viewing the combination of 12.1% revenue growth and the 91.38% earnings growth forecast as a sign that operating leverage could improve if revenue continues to build.

If you are wondering how optimistic investors join the dots between this revenue growth, margin expectations and future profits, the full bull case lays that out in one place. 🐂 STAAR Surgical Bull Case

P/S premium and DCF gap pull valuation in opposite directions

• STAAR trades around 4x P/S compared with roughly 2.9x for the broader US Medical Equipment industry and 0.8x for peers, while a DCF fair value of about US$39.50 sits well above the current share price of US$19.22.
• What stands out to many investors is the tension between paying a higher sales multiple than peers and industry, and a DCF fair value that sits more than US$20 above the current price. This leads some to question whether the premium P/S reflects growth expectations, or whether the modeled fair value is generous given trailing 12 month losses of US$80.4 million.
  • On one side, the 4x P/S versus 0.8x for peers signals that the market is already assigning STAAR a premium for its 12.1% revenue growth rate.
  • On the other, the DCF fair value of roughly US$39.50 compared with the US$19.22 share price suggests the modeled cash flow path is considerably more optimistic than what the current LTM loss profile might imply.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for STAAR Surgical on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

The mix of optimism and caution in this article is only a starting point, so move quickly and check the underlying numbers yourself. To see what has investors encouraged right now, take a closer look at the 2 key rewards.

See What Else Is Out There

STAAR Surgical is still carrying a US$80.4 million annual loss, volatile quarterly EPS and a premium 4x P/S multiple despite ongoing earnings uncertainty.

If that mix of losses and valuation tension feels a bit uncomfortable, you may want to balance it by checking out 77 resilient stocks with low risk scores that aim to prioritise more resilient profiles right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.